Press Releases

Samsung Biologics Reports Third Quarter 2022 Financial Results

Oct 28, 2022, 09:43 AM by
Samsung Biologics a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results.
  • Recorded consolidated revenue of KRW 873 billion in Q3’22

 

  • Recorded consolidated operating profit of KRW 324.7 billion in Q3’22

 

  • Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms

 

Incheon, S. Korea, Oct. 26, 2022 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results, announcing that the company’s cumulative revenue in fiscal year 2022 surpassed KRW 2 trillion.

 

John Rim, CEO of Samsung Biologics, said: “This past quarter saw strong performance and growth due to a consistent momentum in signing new contracts, helping us meet client demand for integrated offerings and deliver long-term value. Not only have we delivered on our commitments by commencing GMP operations of Plant 4 within just 23 months from the start of its construction, we have also developed and launched our next-generation bio-technologies – S-DUAL™ and DEVELOPICK™ – which will help streamline and accelerate the antibody development process to save time and cost for our clients.” 

 

THIRD QUARTER 2022 RESULTS

 

Samsung Biologics in the third fiscal quarter recorded a consolidated revenue of KRW 873 billion, operating profit of KRW 324.7 billion, and net profit of KRW 129.2 billion.

 

[Consolidated Earnings Results]

Q3’22

Q3’21

YoY Change

Q2’22

QoQ

Revenues

873

450.7

+422.3

651.4

+221.6

Operating Profit

324.7

167.4

+157.3

169.7

+155

Net Profit

129.2

131.8

-2.6

152

-22.8


[Unit: KRW billion]

 

FOURTH QUARTER & FISCAL YEAR 2022 OUTLOOK 

 

As previously announced, Samsung Biologics commenced GMP operations of Plant 4, the world’s largest single bio-manufacturing plant, within just 23 months since its groundbreaking. The construction of the 240,000-liter CDMO plant is expected to be completed in 2023, designating Samsung Biologics as the top global manufacturing hub with a total capacity of 604,000 liters, a volume equivalent to over one-fourth of worldwide CMO capacity. 


Samsung Biologics launched its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – a high-yield bispecific antibody platform and a rapid developability assessment platform. 

Samsung Biologics also achieved several business milestones, including the signing of a land-purchasing agreement for Bio Campus II with 30% greater land area for additional capacity and platform growth. Then in August, a $15 million investment through the Samsung Life Science Fund, a joint venture with Samsung C&T, was granted to Senda Biosciences, a U.S.-based biotechnology company committed to fostering core technologies needed to develop next-generation biopharmaceuticals. 

 

In September, Samsung Biologics received EcoVadis’ Gold Sustainability Rating in recognition of its ongoing sustainable management efforts, placing the company within the top 5 percentile. 

For more details on performance and financials, please refer to the Earnings Release.